Article
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) - 1 Mar 2020
van Veggel B, Madeira R Santos J F Vilacha, Hashemi S M S, Paats M S, Monkhorst K, Heideman D A M, Groves M, Radonic T, Smit E F, Schuuring E, van der Wekken A J, de Langen A J
Abstract excerpt
OBJECTIVES: Epidermal growth factor receptor (EGFR) exon 20 insertions comprise 4-10 % of EGFR mutations in non-small cell lung cancer (NSCLC) and are associated with primary resistance to first and second generation EGFR tyrosine kinase inhibitors (TKIs). In vitro and preclinical animal studies have shown that osimertinib exerts antitumor activity against EGFR exon 20 mutation positive NSCLC. We report on a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.